New York, February 9, 2026 — Leads & Copy — Anavex Life Sciences Corp. (Nasdaq: AVXL) reported its financial results for the first quarter of fiscal 2026 and provided updates on its clinical development programs.
The clinical-stage biopharmaceutical company is focused on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders.
Christopher U. Missling, PhD, President and CEO of Anavex, stated the company continues to advance its clinical pipeline, focusing on oral blarcamesine in early Alzheimer’s disease. He noted the company’s commitment to improving the lives of patients with neurological disorders and the therapeutic potential of oral blarcamesine. The company looks forward to working with regulatory agencies in Europe and the U.S. to advance oral blarcamesine as a potential new treatment option.
Anavex anticipates several development milestones:
- Update on regulatory pathway for blarcamesine in early Alzheimer’s disease
- Progress on clinical development program in Parkinson’s disease through targeted approach, potentially addressing the highest disease burden in Parkinson’s disease
- Regulatory and clinical trial update for blarcamesine in Parkinson’s disease
- Regulatory and clinical trial update for blarcamesine in Rett syndrome
- Fragile X development update: Design of Phase 2/3 clinical trial
- Advancing ANAVEX®3-71 towards pivotal clinical studies for the treatment of schizophrenia related disorders
- Progressing collaborative initiatives and strategic partnership activities
- New scientific findings to be presented at upcoming conferences or publications
The company announced its participation as a key industry partner in ACCESS-AD, a European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer’s disease. The program is funded by the European Commission’s Innovative Health Initiative (IHI).
On January 8, 2026, Anavex appointed Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. On January 6, 2026, Anavex announced feedback from the FDA Type C meeting, in which the FDA shared their interest and collaborative approach to Anavex’ development plans.
Anavex also provided an update on the regulatory review in the EU for blarcamesine to treat early Alzheimer’s disease. The CHMP adopted a negative opinion on the marketing authorisation application for blarcamesine, and Anavex requested the EMA to re-examine its opinion.
Anavex announced the presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA, which took place November 26, 2025.
Financial highlights include:
- Cash and cash equivalents of $131.7 million at December 31, 2025, compared to $102.6 million at September 30, 2025.
- Research and development expenses for the quarter of $4.7 million compared to $10.4 million for the comparable quarter of fiscal 2025.
- General and administrative expenses for the quarter of $2.1 million compared to $3.1 million for the comparable quarter of fiscal 2025.
- Net loss for the quarter of $5.7 million, or $0.06 per share, compared to a net loss of $12.1 million, or $0.14 per share for the comparable fourth quarter of fiscal 2025.
Anavex will host a live webcast today at 8:30 am Eastern Time, available on the company’s website. A replay will be available for 30 days.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is focused on developing treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.
Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed clinical trials for Alzheimer’s disease, Parkinson’s disease dementia, and Rett syndrome. ANAVEX®3-71 is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer’s disease in preclinical trials.
Source: Anavex Life Sciences Corp.
